about
sameAs
Myosin heavy chain composition and the economy of contraction in healthy and diseased human myocardiumMyocardial contraction is 5-fold more economical in ventricular than in atrial human tissueTargets for therapy in sarcomeric cardiomyopathiesResearch priorities in sarcomeric cardiomyopathiesIncreased Ca2+-sensitivity of the contractile apparatus in end-stage human heart failure results from altered phosphorylation of contractile proteinsThe effect of myosin light chain 2 dephosphorylation on Ca2+ -sensitivity of force is enhanced in failing human heartsCardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunctionPhosphorylation of protein kinase C sites Ser42/44 decreases Ca(2+)-sensitivity and blunts enhanced length-dependent activation in response to protein kinase A in human cardiomyocytesProtein kinase C alpha and epsilon phosphorylation of troponin and myosin binding protein C reduce Ca2+ sensitivity in human myocardiumContractile dysfunction irrespective of the mutant protein in human hypertrophic cardiomyopathy with normal systolic functionImpaired diastolic function after exchange of endogenous troponin I with C-terminal truncated troponin I in human cardiac muscleWhy does troponin I have so many phosphorylation sites? Fact and fancyGSK3β phosphorylates newly identified site in the proline-alanine-rich region of cardiac myosin-binding protein C and alters cross-bridge cycling kinetics in human: short communicationPerturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutationsAnalysis of cardiac myosin binding protein-C phosphorylation in human heart musclePosttranslational modifications of cardiac troponin T: an overviewLength-dependent activation is modulated by cardiac troponin I bisphosphorylation at Ser23 and Ser24 but not by Thr143 phosphorylationA novel phosphorylation site, Serine 199, in the C-terminus of cardiac troponin I regulates calcium sensitivity and susceptibility to calpain-induced proteolysisValue of Genetic Testing for the Prediction of Long-Term Outcome in Patients With Hypertrophic Cardiomyopathy.In-vivo T1 cardiovascular magnetic resonance study of diffuse myocardial fibrosis in hypertrophic cardiomyopathy.How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance.Cardiac Myosin Binding Protein-C Autoantibodies are Potential Early Indicators of Cardiac Dysfunction and Patient Outcome in Acute Coronary SyndromeGenotype-specific pathogenic effects in human dilated cardiomyopathy.Carriers of the hypertrophic cardiomyopathy MYBPC3 mutation are characterized by reduced myocardial efficiency in the absence of hypertrophy and microvascular dysfunction.The young ones and the old: past & future of science.Troponin I phosphorylation in human myocardium in health and disease.More severe cellular phenotype in human idiopathic dilated cardiomyopathy compared to ischemic heart disease.FHL2 expression and variants in hypertrophic cardiomyopathy.Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness.Peripartum cardiomyopathy and dilated cardiomyopathy: different at heart.PKCα-specific phosphorylation of the troponin complex in human myocardium: a functional and proteomics analysis.Protein changes contributing to right ventricular cardiomyocyte diastolic dysfunction in pulmonary arterial hypertensionDiastolic myofilament dysfunction in the failing human heart.Dexrazoxane pre-treatment protects skinned rat cardiac trabeculae against delayed doxorubicin-induced impairment of crossbridge kinetics.Tachycardia-induced silencing of subcellular Ca2+ signaling in atrial myocytes.Effect of levosimendan on the contractility of muscle fibers from nemaline myopathy patients with mutations in the nebulin gene.Myosin light chain composition in non-failing donor and end-stage failing human ventricular myocardium.Oxidative Stress in Dilated Cardiomyopathy Caused by MYBPC3 Mutation.ADP-stimulated contraction: A predictor of thin-filament activation in cardiac disease.Impact of site-specific phosphorylation of protein kinase A sites Ser23 and Ser24 of cardiac troponin I in human cardiomyocytes
P50
Q24314097-8B4B60A2-0BC0-4C4D-A261-B808E36B87BEQ24336975-1976E0AB-03DE-4DC4-8F93-AD2926463228Q27027023-89794810-DA73-4545-AD86-57F18D8EFBDCQ27694507-F1171476-D974-428A-9818-98482C196D89Q28198289-A852A979-3A23-4E52-9856-CF6B4F351231Q28207282-5EFD58DA-7F8D-4F07-8F36-D39A0C1FA810Q28237729-3417DB81-67FB-4540-8A6B-937A39A21652Q28239800-9DAC2FB8-1A5E-4582-9A01-E0913E1685B1Q28253877-6A2345E5-5893-4ECD-AD24-EE2B8989768AQ28255692-AE2B18DC-A89C-4692-8AEB-BF1CB1F95175Q28267178-CB1C2B97-56C1-4B6C-AA8B-F67C210D6EA2Q28274412-1BBD2DF0-F172-4FC4-882E-0B292EE05890Q28282353-2706C7AE-5B08-4C39-B248-88BE01DD6F88Q28287468-FF8907AC-3962-418E-8F11-A56B7E031962Q28293588-F00969BA-0200-44A9-8B4D-5BAAEB796E16Q28294867-53EE4AFA-550A-4D36-8B4C-4E5E6860D055Q28308168-4E79C28A-3A5C-4070-AFB4-1C3FB71F5484Q28910472-B2E8669C-A253-4D68-983C-603E9C5A99C0Q33167528-B33204C3-8260-4522-AC50-EDB2BD36DFD8Q33634302-2DCD672A-8D15-4C9A-AB5B-A541ED21415CQ33741738-5FA8D1B1-8E83-4EF0-8AD6-94B5ED9D0AB3Q33768996-26BA57C0-30C5-4CBC-B75C-1A36A617C193Q33903336-9EE5AC49-885B-4735-B3D2-19244F24CFF9Q34054904-BC6A8328-409E-40C4-BF54-51037D458AD2Q34161218-8A3A4E3C-BAE3-42AB-8D8C-659D54392B35Q34302767-6F954F7A-7180-4A4C-8344-B7712857FAE3Q34420272-5410F735-8E05-4FF0-AF57-001996C7A48CQ34430364-478D6112-62C6-4818-B604-075DC700B6AFQ34515507-8B26A0BD-D465-460D-8769-CB565ABD79FAQ34969073-317CCDBD-CD2E-4A9C-BEF2-07CC5F03BFC3Q35014341-C6BEE1E4-341C-4E75-85E8-81A8F8A2858CQ35021804-4F3C4FB2-ADAD-4BA3-9299-0C26112DE6E9Q35042592-0CC8F8F5-DC8B-4AA2-A1E2-485CE5979765Q35044266-DB2AF45E-144C-4096-B0B1-5AA8097ABD84Q35140062-5BCFA115-F779-462D-8D70-B60A1D1C1314Q35576373-11AE25B2-4D7D-442A-8DE3-C6FC0C3389FAQ35751461-B9C46828-40ED-4D98-8A29-DDBF4C8F9EB8Q36174383-1A55C997-1117-44C7-B885-EA36D88ACE17Q36394188-61E6D5E3-FCD0-4D92-9135-E5FA856D3C11Q36528069-3C16DC38-4AFA-4466-88B2-60C828DE667F
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Jolanda van der Velden
@ast
Jolanda van der Velden
@en
Jolanda van der Velden
@es
Jolanda van der Velden
@nl
Jolanda van der Velden
@sl
type
label
Jolanda van der Velden
@ast
Jolanda van der Velden
@en
Jolanda van der Velden
@es
Jolanda van der Velden
@nl
Jolanda van der Velden
@sl
prefLabel
Jolanda van der Velden
@ast
Jolanda van der Velden
@en
Jolanda van der Velden
@es
Jolanda van der Velden
@nl
Jolanda van der Velden
@sl
P106
P21
P31
P496
0000-0001-5224-5788